Skip Navigation



Hum. Reprod. Advance Access published online on March 31, 2005
Human Reproduction, doi:10.1093/humrep/deh873
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/7/1814    most recent
deh873v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Eldar-Geva, T.
Right arrow Articles by Spitz, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eldar-Geva, T.
Right arrow Articles by Spitz, I. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received December 29, 2004
Revised February 13, 2005
Accepted February 23, 2005

Article

Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism

Talia Eldar-Geva 1*, Ehud J. Margalioth 2, Michael Gal 2, Avraham Ben-Chetrit 2, Nurit Algur 3, Edit Zylber-Haran 2, Baruch Brooks 2, Michael Huerta 2, and Irving M. Spitz 3

1 IVF Unit, Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem, Israel; Institute of Hormone Research, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem, Israel
2 IVF Unit, Department of Obstetrics and Gynecology, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem, Israel
3 Institute of Hormone Research, Shaare-Zedek Medical Center, Ben Gurion University of the Negev, Jerusalem, Israel

* To whom correspondence should be addressed.
Talia Eldar-Geva, E-mail: gevat{at}szmc.org.il


  Abstract

BACKGROUND: Anti-Mullerian hormone (AMH) is expressed in pre- and small-antral follicles. High serum levels are found in women with polycystic ovaries (PCO), accordant with their increased content of small follicles. To evaluate the relationship between AMH, folliculogenesis and hyperandrogenism, we compared serum AMH levels between women with PCO with and without hyperandrogenism and normal controls during controlled ovarian hyperstimulation (COH). METHODS: Nineteen women with PCO and hyperandrogenism (group A), 10 women with PCO but no hyperandrogenism (group B) and 23 ovulatory women with normal ovarian morphology (group C, controls) underwent COH with the long protocol. Serum levels of AMH, estradiol, androstenedione and follicular tracking were determined before gonadotropins treatment (day 0) and every 2-4 days up to the day of HCG administration. RESULTS: AMH levels declined gradually throughout COH in the three groups, but remained higher in groups A and B compared with the controls. Significantly higher levels were found in group A compared with group B, despite comparable numbers of small follicles. Multiple regression analysis revealed that both the number of small follicles and serum androgens were correlated to AMH. CONCLUSIONS: Women with PCO have higher serum AMH levels during COH than controls. Hyperandrogenism is associated with an additional increase in AMH. It is conceivable that hyperandrogenism may reflect more severe disruption of folliculogenesis in women with PCO or may affect AMH secretion.

Keywords: anti-Mullerian hormone; controlled ovarian hyperstimulation; hyperandrogenism; polycystic ovaries.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
L. G. Nardo, A. P. Yates, S. A. Roberts, P. Pemberton, and I. Laing
The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome
Hum. Reprod., November 1, 2009; 24(11): 2917 - 2923.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S.A. Amer, T.C. Li, and W.L. Ledger
The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy
Hum. Reprod., November 1, 2009; 24(11): 2760 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D.A. Dumesic, M.S. Patankar, D.K. Barnett, T.G. Lesnick, B.A. Hutcherson, and D.H. Abbott
Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys
Hum. Reprod., September 9, 2009; (2009) dep324v1.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. La Marca, F.J. Broekmans, A. Volpe, B.C. Fauser, N.S. Macklon, and on behalf of the ESHRE Special Interest Group for
Anti-Mullerian hormone (AMH): what do we still need to know?
Hum. Reprod., September 1, 2009; 24(9): 2264 - 2275.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.L. Thomson, J.D. Buckley, L.J. Moran, M. Noakes, P.M. Clifton, R.J. Norman, and G.D. Brinkworth
The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment
Hum. Reprod., August 1, 2009; 24(8): 1976 - 1981.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S.M. Carlsen, E. Vanky, and R. Fleming
Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome
Hum. Reprod., July 1, 2009; 24(7): 1732 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E. Diamanti-Kandarakis, A. Piouka, S. Livadas, C. Piperi, I. Katsikis, A. G Papavassiliou, and D. Panidis
Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome
Eur. J. Endocrinol., May 1, 2009; 160(5): 847 - 853.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Das, D.J. Gillott, E. Saridogan, and O. Djahanbakhch
Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome
Hum. Reprod., September 1, 2008; 23(9): 2122 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Catteau-Jonard, P. Pigny, A.-C. Reyss, C. Decanter, E. Poncelet, and D. Dewailly
Changes in Serum Anti-Mullerian Hormone Level during Low-Dose Recombinant Follicular-Stimulating Hormone Therapy for Anovulation in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4138 - 4143.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Moran, M. Noakes, P. M. Clifton, and R. J. Norman
The Use of Anti-Mullerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3796 - 3802.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. S. Wachs, M. S. Coffler, P. J. Malcom, and R. J. Chang
Serum Anti-Mullerian Hormone Concentrations Are Not Altered by Acute Administration of Follicle Stimulating Hormone in Polycystic Ovary Syndrome and Normal Women
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1871 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Pellatt, L. Hanna, M. Brincat, R. Galea, H. Brain, S. Whitehead, and H. Mason
Granulosa Cell Production of Anti-Mullerian Hormone Is Increased in Polycystic Ovaries
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Pigny, S. Jonard, Y. Robert, and D. Dewailly
Serum Anti-Mullerian Hormone as a Surrogate for Antral Follicle Count for Definition of the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 941 - 945.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
J. A Visser, F. H de Jong, J. S E Laven, and A. P N Themmen
Anti-Mullerian hormone: a new marker for ovarian function
Reproduction, January 1, 2006; 131(1): 1 - 9.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.